MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
EQS-News: MorphoSys AG / Key word(s): Delisting Media Release Planegg/Munich, Germany, July 12, 2024 MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act"). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the "SEC") a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) of the Exchange Act, relating to the delisting and deregistration on or about July 25, 2024, with the delisting of the ADSs taking effect no earlier than ten days thereafter. As a result, MorphoSys expects that the last trading day on Nasdaq will be on or about August 2, 2024. Following the delisting, any trading in MorphoSys' ADSs would occur only in privately negotiated sales and potentially on an over-the-counter market if a broker makes a market in the ADSs. There is no guarantee, however, that a broker will make such a market or that trading of the ADSs will continue on an over-the-counter market or otherwise. The Supervisory Board of MorphoSys authorized the delisting of the ADSs as required by the delisting agreement signed by MorphoSys, Novartis BidCo AG and Novartis AG (hereinafter collectively referred to as "Novartis"). On July 4, 2024, Novartis launched its public delisting purchase offer for all outstanding no-par value bearer shares of MorphoSys. In addition, Novartis has informed MorphoSys of its intention to merge MorphoSys into Novartis (the "Merger Squeeze-out"). The conclusion and notarization of the merger agreement between MorphoSys AG and Novartis BidCo Germany AG will take place shortly. The effectiveness of the merger squeeze-out is still subject to approval by the MorphoSys AG Annual General Meeting and the registration of both the transfer resolution and the merger in the commercial register at the seat of MorphoSys AG, as well as the registration of the merger in the commercial register at the seat of Novartis BidCo Germany AG. About MorphoSys Forward-Looking Statements The forward-looking statements contained in this communication represent the judgment of MorphoSys as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: MorphoSys' ability to file a Form 25 and the timing of such filing; the last trading day of the ADSs on the Nasdaq Global Market; MorphoSys' ability to file a Form 15 and the timing of such filing; the timing of effectiveness of the Form 15; the effects of the acquisition of MorphoSys by Novartis AG on relationships with employees, other business partners or governmental entities; that Novartis BidCo AG and Novartis AG may not realize the potential benefits of the acquisition of MorphoSys by Novartis AG; potential operational difficulties with integrating MorphoSys with Novartis AG; that MorphoSys' expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements; MorphoSys' reliance on collaborations with third parties; estimating the commercial potential of MorphoSys' development programs; and other risks indicated in the risk factors included in MorphoSys' filings with the SEC, including MorphoSys' Annual Report on Form 20-F. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this communication. MorphoSys' expressly disclaims any obligation to update any such forward-looking statements in this communication to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact:
12.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
MorphoSys AG / 关键词:退市
MorphoSys宣布自纳斯达克全球市场自愿退市 媒体新闻稿 德国,普兰格/慕尼黑,2024年7月12日 MorphoSys宣布自纳斯达克全球市场自愿撤牌 MorphoSys监事会根据MorphoSys、诺华子公司BidCo AG和诺华制药签署的退市协议要求授权退市。2024年7月4日,诺华发起所有未偿还无面额股票收购报价。 MorphoSys目前预计,将提交《1934年交易所法》第12(b)条下的上市和/或注册撤销通知表格25表,有关从纳斯达克股票市场摘牌和注销手续,时间不早于2024年7月25日的日期,并于之后的十天内生效。因此,MorphoSys预计,纳斯达克的最后交易日为2024年8月2日左右。 另外,诺华已告知MorphoSys有意将MorphoSys并入诺华(拟定的并购)。 MorphoSys AG和诺华子公司BidCo Germany AG之间的合并协议的缔结和公证将很快进行。合并强制注销的有效性仍需获得MorphoSys AG股东大会批准,以及在MorphoSys AG注册地商业登记簿上注册股份转让决议和合并事项,以及在诺华银行子公司德国商业登记簿上注册合并事项。 MorphoSys的使命驱动我们:为癌症患者带来更多的生活。作为一家全球性生物制药公司,我们开发和提供创新药品,旨在重新定义癌症的治疗。MorphoSys总部位于德国Planegg,其美国业务总部位于马萨诸塞州的波士顿。欲了解更多信息,请访问我们 ,并关注我们的Twitter X和LinkedIn。 此通信涉及某些关于MorphoSys、Novartis和退市要约的前瞻性陈述,这些前瞻性陈述涉及重大风险和不确定性。前瞻性陈述包括任何含有“预计”、“相信”、“估计”、“期望”、“意图”、“目标”、“可能”、“计划”、“预测”、“项目”、“寻求”、“目标”、“潜在”、“将”、“可能”、“应该”、“持续”或类似表述的陈述。在此通信中,MorphoSys的前瞻性陈述包括有关完成退市要约和退市的预计时间表;MorphoSys的计划、目标、期望和意图;以及MorphoSys和诺华制药的财务状况、业绩和业务。 关于MorphoSys 前瞻性声明 从业务活动、财务状况、措施、定制内容和存储内部控制等方面发现的与可比企业、可比的市场股权或生产过程相关的差异。也可能会发生环境、政治、法规、经济和其他重大风险或不确定因素的变化等。在风险确认后,德国生物制药公司M0rphosys纳斯达克代码MOR将被注销。 更多信息,请联系:
2024年12月7日 CET/CESt发布企业新闻,由EQS News - EQS Group AG的服务传送。 |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | |
ISIN: | DE0006632003 |
WKN: | 663200 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1945523 |
语言: | 英语 |
公司: | morphosys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
德国 | |
电话: | 电话:+49 (0)89 899 27-0 |
传真: | 传真:+49 (0)89 899 27-222 |
电子邮件: | investors@morphosys.com |
阅读我们的年报 | |
ISIN代码 : | DE0006632003 |
WKN: | 663200 |
上市: | 法兰克福(主板)上市、柏林、杜塞尔多夫、汉堡、汉诺威、慕尼黑、斯图加特、Tradegate Exchange非官方上市、纳斯达克 |
EQS新闻 ID: | 1945523 |
End of News | EQS News Service |
新闻结束 | EQS新闻服务 |